Showing 5,061 - 5,080 results of 5,256 for search 'x86~', query time: 0.88s Refine Results
  1. 5061
  2. 5062
  3. 5063
  4. 5064
  5. 5065

    Danggui-Shaoyao-San Can Ameliorate Alzheimer’s Disease by Inhibiting Hippocampal Neuron Apoptosis: Findings from Serum Pharmacology by Zhang KX, Zhang JW, Jiang YH, Wang YR, Liu ZL, Ding PL, Wang XY, Cui WQ, Xu XQ, Wang YH

    Published 2025-02-01
    “…Kai-Xin Zhang,1 Ji-Wei Zhang,2 Yan-Hong Jiang,1 Yi-Ran Wang,1 Zhen-Ling Liu,1 Peng-Li Ding,1 Xiang-Ying Wang,1 Wen-Qiang Cui,3 Xiang-Qing Xu,3,* Ya-Han Wang3,* 1First College of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, 250000, People’s Republic of China; 2College of Acupuncture and Massage, Shandong University of Traditional Chinese Medicine, Jinan, 250000, People’s Republic of China; 3Department of Neurology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250000, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xiang-Qing Xu, Ya-Han Wang; Department of Neurology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250000, People’s Republic of China, Email [email protected]; [email protected]: Danggui-Shaoyao-San (DSS) is a traditional Chinese medicine prescription with a history of nearly 2000 years, originally widely used for gynecological diseases, and in recent years research has found that DSS also has a good therapeutic effect on Alzheimer’s disease (AD).Purpose: The objective is to investigate the metabolic components of the DSS in the blood and the potential mechanisms for AD.Materials and Methods: Liquid chromatography‒mass spectrometry (LC-MS) combined with gas chromatography‒mass spectrometry (GC-MS) based non-targeted metabolomics were used to conduct in-depth research. …”
    Get full text
    Article
  6. 5066

    USP5 stabilizes YTHDF1 to control cancer immune surveillance through mTORC1-mediated phosphorylation by Na Shao, Lei Xi, Yangfan Lv, Muhammad Idris, Lin Zhang, Ya Cao, Jingyi Xiang, Xi Xu, Belinda X. Ong, Qiongyi Zhang, Xu Peng, Xiaoyan Yue, Feng Xu, Chungang Liu

    Published 2025-02-01
    “…Abstract The N6-methyladenosine binding protein YTHDF1, often upregulated in cancer, promotes tumor growth and hinders immune checkpoint blockade treatment. …”
    Get full text
    Article
  7. 5067
  8. 5068

    Identification of degradation risk areas and delineation of key ecological function areas in Qinling region by Xiaojuan Xu, Dayi Lin, Yue Yang, Jing Liu, Changxin Zou, Naifeng Lin, Fusheng Jiao, Qian Wu, Jie Qiu, Kun Zhang

    Published 2025-02-01
    “…Ecosystem quality increased in 48.07% of the Qinling region. The degradation risk zones of ecosystem quality and function were primarily located in the Sanjiangyuan, the Minshan-Qinghai-Tibet Plateau, and the Loess Plateau in Shaanxi, Henan, and Gansu. …”
    Get full text
    Article
  9. 5069
  10. 5070
  11. 5071

    Analysis of ADR reports of cetuximab based on the FDA adverse event reporting system database by Shuai Zhao, Yan Wang, Xiaoli Deng, Xi Chen, Zhaoyi Lu

    Published 2025-02-01
    “…The main SOCs (Skin and subcutaneous tissue disorders, investigations, metabolism and nutrition disorders, and blood and lymphatic system disorders) accounted for 58.63%. Some AEs were not on the drug label: speech disorder, intervertebral discitis, glomerulonephritis rapidly progressive and disseminated intravascular coagulation. …”
    Get full text
    Article
  12. 5072
  13. 5073
  14. 5074

    Survival feature and trend of female breast cancer: A comprehensive review of survival analysis from cancer registration data by Dan-Dan Tang, Zhuo-Jun Ye, Wan-Wan Liu, Jing Wu, Jing-Yu Tan, Yan Zhang, Qun Xu, Yong-Bing Xiang

    Published 2025-02-01
    “…The prognosis of female breast cancer patients was favorable, with 5-year relative survival rates above 80 % in most regions. The trend in breast cancer survival showed annual increases in most countries but was accompanied by geographical disparities. …”
    Get full text
    Article
  15. 5075
  16. 5076
  17. 5077
  18. 5078
  19. 5079

    Trajectories of systemic immune inflammation index and mortality risk in patients with moderate-to-severe traumatic brain injury: a retrospective cohort study by Zhiyong Tang, Zhiyong Tang, Canlin Liao, Zerui Zhuang, Zhennan Xu, Mingfa Liu, Haixiong Xu

    Published 2025-02-01
    “…Compared to patients in Group 1, those in Groups 2 and 3 had a higher risk of all-cause hospital mortality (odds ratio [OR] 4.09; 95% confidence interval [CI] 1.21, 19.75) and (OR 5.84; 95% CI 1.52, 30.67), respectively. ROC analysis revealed an area under the curve (AUC) of 0.838, sensitivity: 75.0%, and specificity: 83.8% for mortality in this cohort.ConclusionThis study identified three distinct SII trajectories, suggesting that post-TBI SII trajectories are heterogeneous patterns associated with mortality. …”
    Get full text
    Article
  20. 5080